Data analysis of COVID-19 study using Dimerix' treatment DMX-200 is officially under way

Recruitment into a key study into Dimerix’s DMX-200 in all COVID-19 patients has now closed with results expected to start being analysed shortly.

Aussie clinical stage biotech Dimerix (ASX:DXB) today announced that REMAP-CAP has formally closed recruitment of moderate state (non-critically ill) Covid-19 patients to the ACE2 RAS Domain clinical study, including its lead compound DMX-200.

The closure will allow for full results to be analysed and reported. Recruitment of critically ill patients to the trial was closed in February 2022, while recruitment of non-critically ill patients was paused pending further analysis of study safety data.

Dimerix said the study closure in non-critically ill patients is not based on any further safety concerns. Instead, it is a pragmatic decision reflecting the REMAP-CAP International Steering committee’s belief continued recruitment of moderately severe Covid-19 patients would be challenging.

The steering committee notes hospitalisation rates of Covid-19 patients appropriate for the study are generally decreasing globally.

REMAP-CAP team to analyse study results

The study results will be analysed by the REMAP-CAP team and prepared for publication. Dimerix said it will report the outcome as soon as it has been received from REMAP-CAP.

There are four different treatment arms to the REMAP-CAP ACE2 RAS study. Randomised patients receive either no RAS drug, an angiotensin receptor blocker (ARB) alone, an angiotensin converting enzyme (ACE) inhibitor alone or an ARB simultaneously with Dimerix’s lead therapy DMX-200.

Meanwhile, Dimerix continues to drive the ACTION3 Phase 3 global clinical trial study effects of its lead drug, DMX-200, on patients with rare kidney disease focal segmental glomerulosclerosis (FSGS).

Dimerix earlier this month also announced it had entered into an agreement with The Australian Centre for Accelerating Diabetes Innovations (ACADI).

The key agreement will progress its lead drug asset DMX-200 into a new clinical trial in patients with diabetic kidney disease.

The new trial provides another potential market opportunity for Dimerix in addition to other Phase 3 trials into inflammatory diseases which are underway.

This article was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.